Delisting of Everolimus by the Cancer Drug Fund

Kidney Cancer UK has added its voice to call for an overhaul of the delisting process of essential cancer drugs by Cancer Drugs Fund (CDF).
Nick Turkentine, CEO at Kidney Cancer UK, said: “The delisting of Afinitor (everolimus) is terrible news for patients with advanced kidney cancer for whom this is one of the very few clinically effective treatments for this devastating disease. To add insult to injury, the process of delisting does not stand up to scrutiny and the fact that Afinitor is available in other parts of the country makes this abundantly clear.” He concluded: “ We will be working alongside other patient organisations to call for an overhaul of the Cancer Drugs Fund‘s delisting process and to determine how we can challenge this process to ensure all kidney cancer patients have access to the most effective drugs at all stages of their treatment.”